Michael Maciocio - Eyepoint Pharmaceuticals Senior Operations
| EYPT Stock | USD 8.25 0.21 2.48% |
Executive
Michael Maciocio is Senior Operations of Eyepoint Pharmaceuticals
| Address | 480 Pleasant Street, Watertown, MA, United States, 02472 |
| Phone | 617 926 5000 |
| Web | https://eyepointpharma.com |
Eyepoint Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3139) % which means that it has lost $0.3139 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7468) %, meaning that it created substantial loss on money invested by shareholders. Eyepoint Pharmaceuticals' management efficiency ratios could be used to measure how well Eyepoint Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.21 in 2024. Return On Capital Employed is likely to drop to -0.27 in 2024. At this time, Eyepoint Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 372.9 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 17.4 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Yoshihiro Nakagawa | Takeda Pharmaceutical Co | 64 | |
| David McErlane | Catalent | 51 | |
| David JD | Teva Pharma Industries | 61 | |
| Bjarne Tellmann | Haleon plc | 57 | |
| Simon MD | Emergent Biosolutions | N/A | |
| Willie MD | Intracellular Th | N/A | |
| Tanya Zharov | Alvotech | 57 | |
| Christopher OBrien | Neurocrine Biosciences | 67 | |
| Cees Heiman | Bausch Health Companies | N/A | |
| Michelle Pepin | Emergent Biosolutions | N/A | |
| Lisa Evoli | Catalent | 54 | |
| Darin Esq | Neurocrine Biosciences | 58 | |
| Dimitri Grigoriadis | Neurocrine Biosciences | 66 | |
| Placid Jover | Teva Pharma Industries | N/A | |
| David Boyer | Neurocrine Biosciences | 45 | |
| Aimee Lenar | Bausch Health Companies | N/A | |
| Ingrid Delaet | Neurocrine Biosciences | 58 | |
| Jane Sorensen | Neurocrine Biosciences | N/A | |
| JeanJacques Charhon | Bausch Health Companies | 59 | |
| Darin Lippoldt | Neurocrine Biosciences | 58 | |
| Josh Coyle | Bausch Health Companies | N/A | |
Management Performance
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.31 |
Eyepoint Pharmaceuticals Leadership Team
Elected by the shareholders, the Eyepoint Pharmaceuticals' board of directors comprises two types of representatives: Eyepoint Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eyepoint. The board's role is to monitor Eyepoint Pharmaceuticals' management team and ensure that shareholders' interests are well served. Eyepoint Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eyepoint Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Jones, Senior Officer | ||
| Jay MD, Chief Officer | ||
| Michael Pine, Chief Officer | ||
| Ramiro MD, Chief Officer | ||
| Nancy Lurker, President CEO, Independent Director | ||
| Dr MS, Interim Director | ||
| Jennifer Leonard, Chief IT | ||
| Anna Kluczewska, President Ltd | ||
| George Elston, Chief Officer | ||
| Dario Paggiarino, Senior Officer | ||
| Ron Esq, Chief Secretary | ||
| Dario MD, Executive Officer | ||
| Said Saim, Chief Officer | ||
| Isabelle Lefebvre, Chief Officer | ||
| Marcia SellosMoura, Senior Leadership | ||
| Michael Maciocio, Senior Operations | ||
| George CPA, Executive CFO | ||
| David MA, Senior Officer |
Eyepoint Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eyepoint Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (2.27) % | ||||
| Operating Margin | (3.11) % | ||||
| Current Valuation | 345.53 M | ||||
| Shares Outstanding | 68.25 M | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 93.48 % | ||||
| Number Of Shares Shorted | 9.25 M | ||||
| Price To Earning | (2.82) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.